Big biologics bet: China's Innovent gets $100m financing
This article was originally published in Scrip
Executive Summary
A record-breaking private financing for a Chinese biotech has seen bets placed on Suzhou-based Innovent Biologics, which has 10 monoclonal antibodies including four biosimilars in its pipeline.
You may also be interested in...
Ping An Expands Broad Health Interests With New Fund For Global Tech
China’s huge Ping An insurance group is continuing to build its investments in healthcare through a major new Hong Kong-based fund that will seek overseas technologies alongside the company’s steadily expanding interests in innovative drugs.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.
Chinese Language Podcast: BIOSECURE Act, US PD-1 Approval, ADC Updates
Guest speaker and lawyer Kevin Duan joins Brian Yang and Dexter Yan to discuss the planned US BIOSECURE Act, the US approval of BeiGene's anti-PD-1 drug and the latest antibody-drug conjugates in development at Chinese pharma firms.